NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease.
NextRNA Therapeutics has raised $46.8M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
NextRNA Therapeutics's investors include Willett Advisors LLC, Jefferies, Rivas Capital, Lightchain Capital, Evans Capital.
NextRNA Therapeutics is headquartered in Cambridge, United States.
NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease.
NextRNA Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NextRNA Therapeutics — Funding & Investors." VCBacked, March 1, 2022, https://www.vcbacked.co/company/nextrna-therapeutics. Accessed November 15, 2026.
VCBacked. (2022). NextRNA Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/nextrna-therapeutics
{{cite web |title=NextRNA Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nextrna-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at NextRNA Therapeutics? Request a listing update